Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Aleksic, Marko (57211851267)"

Filter results by typing the first few letters
Now showing 1 - 6 of 6
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Correlation of Patient-Reported Outcome (PRO-2) with Endoscopic and Histological Features in Ulcerative Colitis and Crohn's Disease Patients
    (2020)
    Dragasevic, Sanja (56505490700)
    ;
    Sokic-Milutinovic, Aleksandra (55956752600)
    ;
    Stojkovic Lalosevic, Milica (57218133245)
    ;
    Milovanovic, Tamara (55695651200)
    ;
    Djuranovic, Srdjan (6506242160)
    ;
    Jovanovic, Ivan (7005436430)
    ;
    Rajic, Sanja (57216493654)
    ;
    Stojkovic, Mirjana (58776160500)
    ;
    Milicic, Biljana (6603829143)
    ;
    Kmezic, Stefan (57211355401)
    ;
    Oluic, Branislav (57201078229)
    ;
    Aleksic, Marko (57211851267)
    ;
    Pavlovic Markovic, Aleksandra (55110483700)
    ;
    Popovic, Dragan (7201969148)
    Background and Objectives. Determination of inflammatory bowel disease activity determines further therapeutic approach and follow-up. The aim of our study was to investigate correlation between patients' reported symptoms and endoscopic and histological disease activity. Methods. A cross-sectional study was conducted in consecutive newly diagnosed patients with inflammatory bowel disease in a tertiary care referral center. The initial evaluation included patient-reported outcome for stool frequency subscore and rectal bleeding. Endoscopic activity was determined using the Mayo scoring system for ulcerative colitis and the Simple Endoscopic Score for Crohn's disease. Histopathological activity was assessed using a validated numeric scoring system. Results. We included 159 patients (63 Crohn's disease with colonic involvement and 96 with ulcerative colitis). We found significant correlation between the Mayo endoscopic subscoring system and histology activity in ulcerative colitis, while no correlation was found in patients with Crohn's disease. Patient-reported outcome showed inverse correlation with endoscopic and histological activity in Crohn's disease (rs=-0.67; rs=-0.72), while positive correlation was found in ulcerative colitis (rs=0.84; rs=0.75). Interpretation and Conclusions. Patient-reported outcome is a practical and noninvasive tool for assessment of disease activity in ulcerative colitis patients but not in Crohn's disease. © 2020 Sanja Dragasevic et al.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Diagnostic Value of Non-invasive Scoring Systems in the Prediction of Esophageal Varices in Patients with Liver Cirrhosis—Single Center Experience
    (2022)
    Glisic, Tijana (7801650637)
    ;
    Lalosevic, Milica Stojkovic (57218133245)
    ;
    Milovanovic, Tamara (55695651200)
    ;
    Rankovic, Ivan (57192091879)
    ;
    Stojanovic, Marija (57218666738)
    ;
    Toplicanin, Aleksandar (57424315200)
    ;
    Aleksic, Marko (57211851267)
    ;
    Milivojevic, Vladimir (57192082297)
    ;
    Nestorov, Jelena Martinov (57219044106)
    ;
    Lolic, Iva (57424315300)
    ;
    Popovic, Dusan D. (37028828200)
    Background and Objectives: Upper endoscopy is considered the gold standard for screening and diagnosis of esophageal varices (EV). Non-invasive methods for predicting EV have become a research hotspot in recent years. The aim of this study was to assess the role of non-invasive scores in predicting the presence of EV in patients with liver cirrhosis, and to determine the value of these scores in predicting the outcome of patients with cirrhosis presenting with acute variceal bleeding. Materials and Methods: A total of 386 patients with liver cirrhosis were included. The model for end-stage liver disease (MELD), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AST/ALT), AST to platelet ratio index (APRI), fibrosis-4-index (FIB-4), fibrosis index (FI), King’s Score, albumin-bilirubin (ALBI) score, and platelet-albumin-bilirubin (PALBI) score were calculated. The discriminatory capacities of the examined scores in predicting the presence of esophageal varices were tested using receiver operating characteristic (ROC) curves. Results: The ROC curve analysis showed (area under the curve) AUC values of ALBI and PALBI of 0.603, and 0.606, respectively, for the prediction of EV. APRI, MELD, PALBI, King’s, FIB-4, and ALBI scores showed statistically significant correlation with EV bleeding (p < 0.05). AUC of APRI and MELD for predicting EV bleeding were 0.662 and 0.637, respectively. The AUC value of MELD in short-term mortality was 0.761. Conclusions: ALBI and PALBI scores had modest diagnostic accuracy of EVs in liver cirrhosis. APRI and MELD can be used as a reference index for the EV bleeding, and MELD score is best associated with short-term outcome in cirrhotic patients. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Hematological Indices Are Useful in Predicting Complications of Liver Cirrhosis
    (2023)
    Glisic, Tijana (7801650637)
    ;
    Popovic, Dusan D. (37028828200)
    ;
    Lolic, Iva (57424315300)
    ;
    Toplicanin, Aleksandar (57424315200)
    ;
    Jankovic, Katarina (57204734668)
    ;
    Dragasevic, Sanja (56505490700)
    ;
    Aleksic, Marko (57211851267)
    ;
    Stjepanovic, Mihailo (55052044500)
    ;
    Oluic, Branislav (57201078229)
    ;
    Matovic Zaric, Vera (57810934200)
    ;
    Radisavljevic, Mirjana M. (55190828000)
    ;
    Stojkovic Lalosevic, Milica (57218133245)
    Background: Liver cirrhosis is the final stage of chronic liver disease. We aimed to evaluate non-invasive scores as predictors of complications and outcome in cirrhotic patients. Methods: A total of 150 cirrhotic patients were included. Models for end-stage liver disease (MELD), albumin-bilirubin (ALBI) score, neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MoLR), and neutrophil-lymphocyte-albumin ratio (NLA) scores were tested in relation to the development of complications and mortality using receiver operating characteristic (ROC) curves. Results: The ROC curve analysis showed (area under the curve) AUC values of NLR, NLA, ALBI, and MELD of 0.711, 0.730, 0.627, and 0.684, respectively, for short-term mortality. MELD, ALBI, and NLA scores showed a statistically significant correlation with hepatic encephalopathy (p = 0.000 vs. 0.014 vs. 0.040, respectively), and the MELD cut-off value of 16 had a sensitivity of 70% and a specificity of 52% (AUC: 0.671, 95% CI (0.577–0.765)). For the assessment of the presence of ascites, the AUC values for NLA and MoLR were 0.583 and 0.658, respectively, with cut-offs of 11.38 and 0.44. Conclusions: MELD, ALBI, and NLA are reliable predictors of hepatic encephalopathy. NLA and MoLR showed a significant correlation with the presence of ascites, and MELD, ALBI, NLR, and NLA have prognostic value to predict 30-day mortality in cirrhotic patients. © 2023 by the authors.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Hepcidin is a reliable marker of iron deficiency anemia in newly diagnosed patients with inflammatory bowel disease
    (2020)
    Lalosevic, Milica Stojkovic (57218133245)
    ;
    Toncev, Ljubisa (56023913400)
    ;
    Stankovic, Sanja (7005216636)
    ;
    Dragasevic, Sanja (56505490700)
    ;
    Stojkovic, Stefan (58448712900)
    ;
    Jovicic, Ivana (55672227100)
    ;
    Stulic, Milos (55895099100)
    ;
    Culafic, Djordje (6603664463)
    ;
    Milovanovic, Tamara (55695651200)
    ;
    Stojanovic, Marija (57218666738)
    ;
    Aleksic, Marko (57211851267)
    ;
    Stjepanovic, Mihailo (55052044500)
    ;
    Lalosevic, Jovan (57190969635)
    ;
    Kiurski, Stanimir (57220806455)
    ;
    Oluic, Branislav (57201078229)
    ;
    Markovic, Aleksandra Pavlovic (24438035400)
    ;
    Stojkovic, Mirjana (58776160500)
    Background and Aim. Differentiating iron deficiency anemia (IDA) from anemia of chronic disease (ACD) in patients with inflammatory bowel disease (IBD) represents a clinical challenge. Hepcidin is a polypeptide synthetized in the liver, and iron levels or inflammation mostly regulate hepcidin production. Our aim was to determine serum hepcidin levels in patients with inflammatory bowel disease (IBD) as well to investigate whether hepcidin levels correlate with disease activity. Material and Methods. A case-control study was preformed among newly diagnosed IBD patients and same number age- and sex-matched healthy controls. All patients underwent a total ileocolonoscopy. Complete blood count was obtained in addition to inflammatory markers (CRP, erythrocyte sedimentation rate-ESR). Serum levels of hepcidin were determined with commercially available enzyme-linked immunosorbent assay (DRG Instruments Marburg, Germany). Serum iron, TIBC, and UIBC were assessed with an electrochemiluminesence immunoassay, and soluble transferrin receptor (sTfR) was assessed using an immunoturbidimetric method. Mayo score and CDAI, respectively, were calculated for each patient. Statistical analyses were performed using the SPSS software version 20.0 for Windows. Results. There was a high statistically significant difference between IBD patients and controls in levels of hepcidin (P < 0:01). Namely, serum hepcidin levels were significantly higher in the control group. There was no statistically significant correlation of serum hepcidin with CRP, Mayo score, or CDAI, respectively (P > 0:05). However, we have found a statistically significant negative correlation of sTfR and TIBC with hepcidin (P < 0:01). Conclusion. Results of our study suggest that hepcidin is a reliable marker of IDA in patients with IBD, and it could be used in routine clinical practice when determining adequate therapy in these patients. Copyright © 2020 Stojkovic Lalosevic Milica et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Hepcidin is a reliable marker of iron deficiency anemia in newly diagnosed patients with inflammatory bowel disease
    (2020)
    Lalosevic, Milica Stojkovic (57218133245)
    ;
    Toncev, Ljubisa (56023913400)
    ;
    Stankovic, Sanja (7005216636)
    ;
    Dragasevic, Sanja (56505490700)
    ;
    Stojkovic, Stefan (58448712900)
    ;
    Jovicic, Ivana (55672227100)
    ;
    Stulic, Milos (55895099100)
    ;
    Culafic, Djordje (6603664463)
    ;
    Milovanovic, Tamara (55695651200)
    ;
    Stojanovic, Marija (57218666738)
    ;
    Aleksic, Marko (57211851267)
    ;
    Stjepanovic, Mihailo (55052044500)
    ;
    Lalosevic, Jovan (57190969635)
    ;
    Kiurski, Stanimir (57220806455)
    ;
    Oluic, Branislav (57201078229)
    ;
    Markovic, Aleksandra Pavlovic (24438035400)
    ;
    Stojkovic, Mirjana (58776160500)
    Background and Aim. Differentiating iron deficiency anemia (IDA) from anemia of chronic disease (ACD) in patients with inflammatory bowel disease (IBD) represents a clinical challenge. Hepcidin is a polypeptide synthetized in the liver, and iron levels or inflammation mostly regulate hepcidin production. Our aim was to determine serum hepcidin levels in patients with inflammatory bowel disease (IBD) as well to investigate whether hepcidin levels correlate with disease activity. Material and Methods. A case-control study was preformed among newly diagnosed IBD patients and same number age- and sex-matched healthy controls. All patients underwent a total ileocolonoscopy. Complete blood count was obtained in addition to inflammatory markers (CRP, erythrocyte sedimentation rate-ESR). Serum levels of hepcidin were determined with commercially available enzyme-linked immunosorbent assay (DRG Instruments Marburg, Germany). Serum iron, TIBC, and UIBC were assessed with an electrochemiluminesence immunoassay, and soluble transferrin receptor (sTfR) was assessed using an immunoturbidimetric method. Mayo score and CDAI, respectively, were calculated for each patient. Statistical analyses were performed using the SPSS software version 20.0 for Windows. Results. There was a high statistically significant difference between IBD patients and controls in levels of hepcidin (P < 0:01). Namely, serum hepcidin levels were significantly higher in the control group. There was no statistically significant correlation of serum hepcidin with CRP, Mayo score, or CDAI, respectively (P > 0:05). However, we have found a statistically significant negative correlation of sTfR and TIBC with hepcidin (P < 0:01). Conclusion. Results of our study suggest that hepcidin is a reliable marker of IDA in patients with IBD, and it could be used in routine clinical practice when determining adequate therapy in these patients. Copyright © 2020 Stojkovic Lalosevic Milica et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Intestinal Ultrasonography as a Tool for Monitoring Disease Activity in Patients with Ulcerative Colitis
    (2022)
    Stojkovic Lalosevic, Milica (57218133245)
    ;
    Sokic Milutinovic, Aleksandra (55956752600)
    ;
    Matovic Zaric, Vera (57810934200)
    ;
    Lolic, Iva (57424315300)
    ;
    Toplicanin, Aleksandar (57424315200)
    ;
    Dragasevic, Sanja (56505490700)
    ;
    Stojkovic, Mirjana (58776160500)
    ;
    Stojanovic, Marija (57218666738)
    ;
    Aleksic, Marko (57211851267)
    ;
    Stjepanovic, Mihailo (55052044500)
    ;
    Martinov Nestorov, Jelena (16230832200)
    ;
    Popovic, Dusan Dj. (37028828200)
    ;
    Glisic, Tijana (7801650637)
    Background. Ultrasonography is a noninvasive, inexpensive, and widely available diagnostic tool. In the last two decades, the development of ultrasound techniques and equipment has significantly increased the usage of intestine ultrasound (US) in the assessment of the gastrointestinal tract in patients with inflammatory bowel disease (IBD). Although current guidelines suggest routine utilization of US in patients with Crohn's disease, data regarding US usage in ulcerative colitis are still scarce. We aimed to assess the reliability of intestinal ultrasonography in the assessment of disease activity and extension of patients with ulcerative colitis. Methods. Fifty-five patients with a histologically confirmed diagnosis of ulcerative colitis, treated at University Clinical Center of Serbia in the period from 2019 to 2022 were included in this retrospective observational study. The data were obtained from the patient's medical records including history, laboratory, US, and endoscopy findings. US examined parameters were as following: bowel wall thickness (BWT), presence of fat wrapping, wall layer stratification, mesenteric hypertrophy, presence of enlarged mesenteric lymph nodes, and absence or presence of ascites. Results. Our results suggest that there is a strong correlation of BWT and colonoscopy findings regarding disease extension (r = 0.524, p=0.01, p<0.05). Furthermore, our results have shown a statistically significant correlation of BWT with the Mayo endoscopic score (r = 0.434, p=0.01, p<0.05), disease activity score (r = 0.369,p=0.01, p<0.05), degree of ulcerative colitis burden of luminal inflammation (r = 0.366, p=0.01, p<0.05), and Geboes index (r = 0.298, p=0.027, p<0.05). Overall accuracy of US for disease extension and activity was statistically significant (p<0.05). Conclusions. Our results suggest that US is a moderately accurate method for the assessment of disease activity and localization in patients with UC. © 2022 Milica Stojkovic Lalosevic et al.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback